Enregistrement - Lobbyistes-conseils

Objets

• Affaires autochtones
• Agriculture
• Arts et culture
• Commerce intérieur
• Commerce international
• Défense
• Développement économique
• Développement régional
• Éducation
• Emploi et formation
• Énergie
• Environnement
• Foresterie
• Immigration
• Impôts et finances
• Industrie
• Infrastructure
• Institutions financières
• Justice et application des lois
• Marchés publics
• Mines
• Pêches
• Petites entreprises
• Propriété intellectuelle
• Questions constitutionnelles
• Questions touchant les consommateurs
• Radiodiffusion
• Recherche et développement
• Relations internationales
• Santé
• Sciences et technologies
• Sports
• Télécommunications
• Tourisme
• Transports
• Travail

Détails sur l'objet

Politique ou Programme

• Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
• Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
• Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
• Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
• Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
• Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
• Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
• Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
• Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
• Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
• Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
• The government's Science and Technology Strategy potential policies & programs pertaining to the biopharmaceutical industry
• World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
• World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
• World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"

Proposition législative, Projet de loi ou résolution

• Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
• Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products.
• Income Tax Act as it relates to biopharmaceutical products
• Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products

Proposition législative, Projet de loi ou résolution, Règlement

• Canadian Environmental Protection Act and Regulations in respect of modern science-based regulations to reflect rapidly changing new technologies.
• Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.

Règlement

• Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
• Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
• New Substances Notification Regulations as it relates to the biopharmaceutical industry
• Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
• Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
• Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
• Smart Regulations as it relates to the biopharmaceutical industry

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Affaires mondiales Canada (AMC)
• Agence de la santé publique du Canada (ASPC)
• Agence du revenu du Canada (ARC)
• Agriculture et Agroalimentaire Canada (AAC)
• Anciens Combattants Canada (ACC)
• Bureau du Conseil privé (BCP)
• Cabinet du Premier ministre (CPM)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Conseil de recherches en sciences naturelles et en génie (CRSNG)
• Conseil national de recherches (CNRC)
• Emploi et Développement social Canada (EDSC)
• Environnement et Changement climatique Canada (ECCC)
• Finances Canada (FIN)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Instituts de recherche en santé du Canada (IRSC)
• Justice Canada (JC)
• Pêches et Océans Canada (MPO)
• Ressources naturelles Canada (RNCan)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sénat du Canada
• Statistique Canada (StatCan)
• Tribunal canadien du commerce extérieur (TCCE)
• Tribunal de la concurrence (TC)

Adresse :
55 Metcalfe Street, Suite 1220
Ottawa, ON  K1P 6L5
Canada

Numéro de téléphone : 613-236-0455
Adresse Web : http://innovativemedicines.ca/

Représentant du client

Pamela Fralick, President

Renseignements sur la société mère

Innovative Medicines Canada n'est pas une filiale d'une société mère.